The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis

British Journal of Pharmacology

Volumn 165, Issue 3, 2012, Pages 729-740

  Camuesco, D ^a   Rodriguez Cabezas M E ^a   Garrido Mesa, N ^a   Cueto Sola, M ^a   Bailon E ^a   Comalada, M ^b   Arribas, B ^a   Merlos, M ^c   Balsa, D ^c   Zarzuelo, A ^a   Janer, G ^c   Xaus, J ^c   Roman J ^c   Galvez J ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^c Drug Development and Clinical Research   (Spain)

Author keywords

5 ASA; dersalazine sodium; experimental colitis; IL 17; PAF antagonist

Indexed keywords

ALPHA ACTIN; DERSALAZINE; DEXTRAN SULFATE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESALAZINE; MYELOPEROXIDASE; SALAZOSULFAPYRIDINE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UR 12715;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DOWN REGULATION; DRUG DOSE COMPARISON; ENZYME ACTIVITY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; TREATMENT OUTCOME;

AMINOSALICYLIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS; AZA COMPOUNDS; AZO COMPOUNDS; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLATELET ACTIVATING FACTOR; RATS; RATS, WISTAR; TRINITROBENZENESULFONIC ACID;

EID: 84855692561     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01598.x     Document Type: Article

References (35)

1. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, et al,. (2009). Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 15: 341-352.
2. Arribas B, Rodríguez-Cabezas ME, Camuesco D, Comalada M, Bailõn E, Utrilla P, et al,. (2009). A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br J Pharmacol 157: 1024-1033.
3. Camuesco D, Comalada M, Rodríguez-Cabezas ME, Nieto A, Lorente MD, Concha A, et al,. (2004). The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br J Pharmacol 143: 908-918. (Pubitemid 39664850)
4. Camuesco D, Peran L, Comalada M, Nieto A, Di Stasi LC, Rodriguez-Cabezas ME, et al,. (2005). Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis. Inflamm Bowel Dis 11: 265-271. (Pubitemid 40439681)
5. Chao W, Olson MS, (1993). Platelet-activating factor: receptors and signal transduction. Biochem J 292: 617-629. (Pubitemid 23210185)
6. Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, Gálvez J, et al,. (2005). In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol 35: 584-592. (Pubitemid 40331335)
7. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM, (2008). Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 324: 23-33. (Pubitemid 350294165)
8. Edwards LJ, Constantinescu CS, (2009). Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases. Inflamm Allergy Drug Targets 8: 182-190.
9. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, et al,. (1996). Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157: 1261-1270. (Pubitemid 126449643)
10. Gálvez J, Garrido M, Merlos M, Torres MI, Zarzuelo A, (2000). Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat. Br J Pharmacol 130: 1949-1959. (Pubitemid 30655808)
11. Gálvez J, Garrido M, Rodríguez-Cabezas ME, Ramis I, de Medina FS, Merlos M, et al,. (2003). The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production. Inflamm Bowel Dis 9: 363-371. (Pubitemid 37461447)
12. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, et al,. (2010). LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis 62: 929-939.
13. Hsueh W, Caplan MS, Qu XW, Tan XD, De Plaen IG, Gonzalez-Crussi F, (2003). Neonatal necrotizing enterocolitis: clinical considerations and pathogenetic concepts. Pediatr Dev Pathol 6: 6-23. (Pubitemid 36323623)
14. Kaiser GC, Yan F, Polk DB, (1999). Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 116: 602-609. (Pubitemid 29106768)
15. Krawisz JE, Sharon P, Stenson WF, (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87: 1344-1350. (Pubitemid 15201434)
16. Liu ZJ, Yadav PK, Su JL, Wang JS, Fei K, (2009). Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 15: 5784-5788.
17. Loftus EV Jr, Kane SV, Bjorkman D, (2004). Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 19: 179-189. (Pubitemid 38174887)
18. Mahida YR, Lamming CE, Gallagher A, Hawthorne AB, Hawkey CJ, (1991). 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 32: 50-54.
19. Melgar S, Karlsson A, Michaàlsson E, (2005). Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2288: G1328-G1338. (Pubitemid 40741088)
20. Nielsen OH, Munck LK, (2007). Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 4: 160-170. (Pubitemid 46416252)
21. Nielsen OH, Verspaget HW, Elmgreen J, (1998). Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment Pharmacol Ther 2: 203-211.
22. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R, (1990). A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702. (Pubitemid 20069706)
23. Patel H, Barr A, Jeejeebhoy KN, (2009). Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 23: 170-176.
24. Peppercorn MA, Goldman P, (1972). The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 181: 555-562.
25. Sarra M, Pallone F, Macdonald TT, Monteleone G, (2010). IL-23/IL-17 axis in IBD. Inflamm Bowel Dis 16: 1808-1813.
26. Siegel CA, (2011). Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther 33: 23-32.
27. Singh TP, Huettner B, Koefeler H, Mayer G, Bambach I, Wallbrecht K, et al,. (2011). Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice. Am J Pathol 178: 699-708.
28. Sobhani I, Hochlaf S, Denizot Y, Vissuzaine C, Rene E, Benveniste J, et al,. (1992). Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. Gut 33: 1220-1225.
29. Stenson WF, Lobos E, (1982). Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 69: 494-497. (Pubitemid 12177629)
30. Sutherland LR, MacDonald JK, (2006a). Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (2): CD000543.
31. Sutherland LR, MacDonald JK, (2006b). Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (2): CD000544.
32. Thyssen E, Turk J, Bohrer A, Stenson WF, (1996). Quantification of distinct molecular species of platelet activating factor in ulcerative colitis. Lipids 31 (Suppl.): S255-S259.
33. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al,. (2001). Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194: 519-527. (Pubitemid 32835046)
34. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, et al,. (2006). IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310-1316.
35. Zhang Z, Hinrichs DJ, Lu H, Chen H, Zhong W, Kolls JK, (2010). After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease? Int Immunopharmacol 7: 409-416. (Pubitemid 46275549)